

IN THE U.S. PATENT AND TRADEMARK OFFICE

Applicant: JENSEN, Bo Skaaning et al. Conf.:  
Appl. No.: New Group:  
Filed: May 15, 2001 Examiner:  
For: ION CHANNEL MODULATING AGENTS

L E T T E R

Assistant Commissioner for Patents  
Washington, DC 20231

May 15, 2001

Sir:

Under the provisions of 35 U.S.C. § 119 and 37 C.F.R. § 1.55(a), the applicant(s) hereby claim(s) the right of priority based on the following application(s):


<u>Country</u>	<u>Application No.</u>	<u>Filed</u>
DENMARK	PA 1998 01722	December 22, 1998
DENMARK	PA 1999 00403	March 23, 1999
DENMARK	PA 1999 00660	May 12, 1999

A certified copy of the above-noted application(s) is(are) attached hereto.

If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or credit any overpayment to Deposit Account No. 02-2448 for any additional fee required under 37 C.F.R. §§ 1.16 or 1.17; particularly, extension of time fees.

Respectfully submitted,

BIRCH, STEWART, KOLASCH & BIRCH, LLP

By   
Gerald M. Murphy, Jr., #28,977

GMM/cgc  
2815-0159P

P.O. Box 747  
Falls Church, VA 22040-0747  
(703) 205-8000

Attachment



2815-059P  
May 15, 2001  
1003

JC997 U.S. PTO  
09/854694  
05/15/01

# Kongeriget Danmark

Patent application No.: PA 1998 01722  
Date of filing: 22 December 1998  
Applicant: NeuroSearch A/S  
Smedeland 26B  
DK-2600 Glostrup

This is to certify the correctness of the following information;

The attached photocopy is a true copy of the following document:

- The specification, claims and abstract as filed with the application on the filing date indicated above.



Patent- og  
Varemærkestyrelsen  
Erhvervsministeriet

TAASTRUP 27 March 2001

Lizzi Vester  
Head of Section



subfamilies: Voltage-activated  $K^+$  channels ( $K_v$ ), long QT related  $K^+$  channels ( $K_vLQT$ ), inward rectifiers ( $K_{IR}$ ), two-pore  $K^+$  channels ( $K_{TP}$ ), and calcium-activated  $K^+$  channels ( $K_{Ca}$ ).

The latter group, the  $Ca^{2+}$ -activated  $K^+$  channels, consists of three well-defined subtypes: SK channels, IK channels and BK channels. SK, IK and BK refer to the single-channel conductance (Small, Intermediate and Big conductance K channel). The SK, IK, and BK channels exhibit differences in e.g. voltage- and calcium-sensitivity, pharmacology, distribution and function.

$Ca^{2+}$ -activated SK channels are present in many central neurons and ganglia, where their primary function is to hyperpolarize nerve cells following one or several action potentials to prevent long trains of epileptogenic activity to occur. The SK channels are also present in several peripheral cells including skeletal muscle, gland cells, liver cells, and T-lymphocytes.

The significance of SK channels in normal skeletal muscle is not clear, but their number is significantly increased in denervated muscle, and the large number of SK channels in the muscle of patients with myotonic muscle dystrophia suggest a role in the pathogenesis of the disease.

A number of blockers of SK channels exist, e.g. apamin, atracurium, pancuronium, and tubocurarine, and they are all positively charged molecules which act as pore blockers.

The  $Ca^{2+}$ -activated IK channel shares a number of characteristics with the  $Ca^{2+}$ -activated SK channel, since it is highly K-selective, is activated by sub-micromolar concentrations of  $Ca^{2+}$ , and has an inwardly rectifying conductance. However, there are also striking differences. The unit conductance of the IK channel is 4-5 fold higher than that of the SK channel, and the distribution of the IK channel is restricted to the blood and vasculature. Thus, the IK channel is not expressed in the nervous system and in muscle, but in endothelial cells, cells of epithelial origin and in red blood cells.

In the red blood cells, where the IK channel has been denominated the Gardos channel, a rise in the concentration of intracellular  $Ca^{2+}$  opens the channel and causes potassium loss and cell dehydration, a condition which is exacerbated in sickle cell anemia. Promising therapeutic approaches for sickle cell anemia involve specific block of the IK channel.

IK channels have also been implicated in the microvasculature of the kidney, where they may be responsible for the vasodilatory effects of bradykinin. The decrease in blood pressure during septic shock is caused by an increased NO production by the endothelial cells, and the IK channels in these cells are responsible  
 5 for maintaining the  $\text{Ca}^{2+}$  influx activating the  $\text{Ca}^{2+}$ -sensitive NO-synthase.

In brain capillary endothelial cells, IK channels, activated by endothelin that is produced by neurons and glia, shunt excess  $\text{K}^+$  into the blood. Neurotrophilic granulocytes, i.e. mobile phagocytic cells that defend the body against microbial invaders, undergo large depolarisation subsequent to agonistic stimulation, and IK  
 10 channels have been implicated in depolarising the stimulated granulocyte.


The  $\text{Ca}^{2+}$ -activated BK channels present in many cells including most central and peripheral nerve cells, striated muscle cells, cardiac cells, smooth muscle cells of the airways, the vasculature, the gastrointestinal tract and bladder, in endo- and exocrine glands including pancreatic b-cells and in kidney tubules.

15

### SUMMARY OF THE INVENTION

According to the present invention it has now been found that a particular group of chemical compounds possess valuable activity as modulators of  $\text{SK}_{\text{Ca}}$ ,  $\text{IK}_{\text{Ca}}$   
 20 and/or  $\text{BK}_{\text{Ca}}$  channels.

In its first aspect the invention relates to novel chemical compounds represented by the general formula



wherein

25 A and B, independently of each another represents a group of the formula - $(\text{CH}_2)_n$ -, of the formula  $-(\text{CH}_2)_n\text{-Y-}$  (in either direction), or of the formula  $-(\text{CH}_2)_n\text{-Y-}(\text{CH}_2)_m$ -, in which formulas n and m independently of each another represents 0, 1, 2 or 3, and Y represents O, S, or  $\text{NR}'$ , wherein  $\text{R}'$  represents hydrogen or alkyl;

$\text{R}^1$  and  $\text{R}^2$  independently of each another represents an alkyl group; a  
 30 mono- or polycyclic aryl group, which aryl group may optionally be substituted one or more times with a substituent selected from the group consisting of halogen,  $\text{CF}_3$ , CN,

amino, nitro, alkoxy, alkyl, alkenyl, alkynyl, phenyl or amido; an aralkyl group; a mono- or poly-heterocyclic group, which heterocyclic group may optionally be substituted one or more times with a substituent selected from the group consisting of halogen,  $\text{CF}_3$ , CN, amino, nitro, alkoxy, alkyl, alkenyl, alkynyl, phenyl or amido; or a hetero-alkyl group, which hetero-alkyl group may optionally be substituted one or more times with a substituent selected from the group consisting of halogen,  $\text{CF}_3$ , CN, amino, nitro, alkoxy, alkyl, alkenyl, alkynyl, phenyl or amido;

$\text{R}^3$  and  $\text{R}^4$  independently of each another represents cyano (CN), an acyl group of the formula  $\text{COOR}'$ , an oxo group of the formula  $\text{COR}'$ , or an ether group of the formula  $\text{CH}_2\text{OR}'$ , in which groups  $\text{R}'$  represents hydrogen, alkyl, cycloalkyl, or  $\text{NR}''\text{R}'''$ , wherein  $\text{R}''$  and  $\text{R}'''$  independently of each another represents hydrogen or alkyl.

In a second aspect, the invention provides a pharmaceutical composition comprising a chemical compound of the invention for the treatment or alleviation of diseases or conditions responsive to modulation of  $\text{SK}_{\text{Ca}}$ ,  $\text{IK}_{\text{Ca}}$  and/or  $\text{BK}_{\text{Ca}}$  channels.

The SK/IK/BK channel modulating agents of the invention are useful for the treatment or alleviation of diseases or conditions responsive to modulation of  $\text{SK}_{\text{Ca}}$ ,  $\text{IK}_{\text{Ca}}$  and/or  $\text{BK}_{\text{Ca}}$  channels.

20

## DETAILED DISCLOSURE OF THE INVENTION

According to the present invention it has now been found that a particular group of chemical compounds possess valuable activity as modulators of  $\text{SK}_{\text{Ca}}$ ,  $\text{IK}_{\text{Ca}}$  and/or  $\text{BK}_{\text{Ca}}$  channels.


25

### SK/IK/BK Modulating Agents

In the context of this invention, chemical compounds capable of affecting  $\text{SK}_{\text{Ca}}$ ,  $\text{IK}_{\text{Ca}}$  and/or  $\text{BK}_{\text{Ca}}$  channels are designated SK/IK/BK channel modulating agents. The SK/IK/BK channel modulating agents of the invention may affect the ion channels by opening (activating) the channels or by inhibiting (blocking) the channels.

30

The SK/IK/BK channel modulating agents of the invention are represented by the following general formula




wherein

A and B, independently of each another represents a group of the formula  $-(\text{CH}_2)_n-$ , of the formula  $-(\text{CH}_2)_n\text{-Y-}$  (in either direction), or of the formula  $-(\text{CH}_2)_n\text{-Y-}(\text{CH}_2)_m-$ , in which formulas  $n$  and  $m$  independently of each another represents 0, 1, 2 or 3, and  $\text{Y}$  represents O, S, or  $\text{NR}'$ , wherein  $\text{R}'$  represents hydrogen or alkyl;

$\text{R}^1$  and  $\text{R}^2$  independently of each another represents an alkyl group; a mono- or polycyclic aryl group, which aryl group may optionally be substituted one or more times with a substituent selected from the group consisting of halogen,  $\text{CF}_3$ , CN, amino, nitro, alkoxy, alkyl, alkenyl, alkynyl, phenyl or amido; an aralkyl group; a mono- or poly-heterocyclic group, which heterocyclic group may optionally be substituted one or more times with a substituent selected from the group consisting of halogen,  $\text{CF}_3$ , CN, amino, nitro, alkoxy, alkyl, alkenyl, alkynyl, phenyl or amido; or a hetero-alkyl group, which hetero-alkyl group may optionally be substituted one or more times with a substituent selected from the group consisting of halogen,  $\text{CF}_3$ , CN, amino, nitro, alkoxy, alkyl, alkenyl, alkynyl, phenyl or amido;

$\text{R}^3$  and  $\text{R}^4$  independently of each another represents cyano (CN), an acyl group of the formula  $\text{COOR}'$ , an oxo group of the formula  $\text{COR}'$ , or an ether group of the formula  $\text{CH}_2\text{OR}'$ , in which groups  $\text{R}'$  represents hydrogen, alkyl, cycloalkyl, or  $\text{NR}''\text{R}'''$ , wherein  $\text{R}''$  and  $\text{R}'''$  independently of each another represents hydrogen or alkyl.

In another embodiment, the chemical compound of the invention is a malonic acid ester derivative of the general formula




wherein

A, B,  $\text{R}^1$  and  $\text{R}^2$  are as defined above, and

$R^5$  and  $R^6$  independently of each another represents hydrogen, alkyl, cycloalkyl, or  $NR''R'''$ , wherein  $R''$  and  $R'''$  independently of each another represents hydrogen or alkyl.

In a third embodiment, the chemical compound of the invention is a malonic acid ester derivative of formula (II), in which  $R^5$  and  $R^6$  together form a heterocyclic 6-9 membered ring to give a diester derivative of the general formula




wherein

A, B,  $R^1$  and  $R^2$  are as defined above, and

X represents a saturated or unsaturated carbon chain of the formula  $-(CH_2)_n-$ , wherein n is 1, 2, 3 or 4; of the formula  $-CH_2-CH=CH-CH_2-$ ; of the formula  $-CH=CH-CH_2-CH_2-$  (in either direction); or of the formula  $-CH_2-C\equiv C-CH_2-$ .

In a fourth embodiment, the chemical compound of the invention is an oxo derivative of the general formula




wherein

A, B,  $R^1$  and  $R^2$  are as defined above, and

$R^5$  and  $R^6$  independently of each another represents hydrogen, alkyl, cycloalkyl, or  $NR''R'''$ , wherein  $R''$  and  $R'''$  independently of each another represents hydrogen or alkyl.

In a fourth embodiment, the chemical compound of the invention is an ether derivative of the general formula



wherein

A, B,  $R^1$  and  $R^2$  are as defined above, and



R<sup>5</sup> and R<sup>6</sup> independently of each another represents hydrogen, alkyl, cycloalkyl, or NR<sup>''</sup>R<sup>'''</sup>, wherein R<sup>''</sup> and R<sup>'''</sup> independently of each another represents hydrogen or alkyl.

In a more preferred embodiment, the chemical compound of the invention is represented by any of formulas I-V, in which formulas R<sup>1</sup> and R<sup>2</sup> independently of each another represents an alkyl group; a phenyl or a benzyl group, which phenyl and benzyl groups may optionally be substituted one or more times with substituent selected from the group consisting of halogen, CF<sub>3</sub>, CN, amino or nitro; a mono-heterocyclic group, which heterocyclic group may optionally be substituted one or more times with substituent selected from the group consisting of halogen, CF<sub>3</sub>, CN, amino or nitro; a heteroalkyl group, wherein the heterocyclic group a mono-heterocyclic group, which heterocyclic group may optionally be substituted one or more times with substituent selected from the group consisting of halogen, CF<sub>3</sub>, CN, amino or nitro.

In another preferred embodiment, the chemical compound of the invention is represented by any of formulas I-V, in which formulas R<sup>1</sup> and R<sup>2</sup> independently of each another represents phenyl, 1-, 2 or 3-chlorophenyl, 1-, 2- or 3-chlorobenzyl, 1-, 2- or 3-nitrophenyl, 1-, 2- or 3-nitrobenzyl, 1-, 2 or 3-trifluoromethylphenyl, 1-, 2- or 3-trifluoromethylbenzyl, or 1-nitro-3-trifluoromethyl-5-chlorophenyl, 1-nitro-3-trifluoromethyl-5-chlorobenzyl.

In a third preferred embodiment, the chemical compound of the invention is represented by any of formulas I-V, wherein the mono-heterocyclic group is an aromatic heterocyclic monocyclic group, in particular 1,3,2,4- or 1,3,4,5-dioxadiazolyl, dioxatriazinyl, dioxazinyl, 1,2,3-, 1,2,4-, 1,3,2- or 1,3,4-dioxazolyl, 1,3,2,4- or 1,3,4,5-dithiadiazolyl, dithiatriazinyl, dithiazinyl, 1,2,3-dithiazolyl, furanyl, furazanyl, imidazolyl, isoimidazolyl, 2-isoimidazolyl, isoindazolyl, isothiazolyl, isoxazolyl, 1,2,3-, 1,2,4-, 1,2,5- or 1,3,4-oxadiazolyl, oxatetrazinyl, oxatriazinyl, 1,2,3,4- or 1,2,3,5-oxatriazolyl, oxazolyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridinyl, pyrimidinyl, pyrrolyl (azolyl), 1,2,3,4- or 2,1,3,4-tetrazolyl, thiadiazolyl, thiazolyl, thienyl, 1,2,3-, 1,2,4- or 1,3,5-triazinyl, or 1,2,3-, 1,2,4-, 2,1,3- or 4,1,2-triazolyl.

In a third preferred embodiment, the chemical compound of the invention is represented by any of formulas I-V, wherein the mono-heterocyclic group is 2-furanyl, 3-furanyl, 2-, 4- or 5-imidazolyl, 3-, 4- or 5-isoxazolyl, 1-, 2- or 3-pyridinyl, or 1- or 2-

thienyl. In a more preferred embodiment, the mono-heterocyclic group is 4-(3,5-dimethyl)-isoxazolyl.

In a fourth preferred embodiment, the chemical compound of the invention is represented by any of formulas I-V, wherein the mono-heterocyclic group is a saturated or partially saturated heterocyclic monocyclic group, in particular 1,3,5,6,2-dioxadiazinyl, 1,2,3,4,5-, 1,2,3,5,4-dioxadiazolyl, dioxanyl, 1,3-dioxolyl, 1,3,5,6,2-dithiadiazinyl, 1,2,3,4,5- or 1,2,3,5,4-dithiadiazolyl, 2-isoimidazolyl, isopyrrolyl, isotetrazolyl, 1,2,3- or 1,2,4-isotriazolyl, morpholinyl, oxadiazinyl, 1,2,4-, 1,2,6-, 1,3,2-, 1,3,6- or 1,4,2-oxazinyl, piperazinyl, piperidinyl, 1,2-, 1,3- or 1,4-pyranyl, or pyrrolidinyl.

In a fifth preferred embodiment, the chemical compound of the invention is represented by any of formulas I-V, wherein the mono-heterocyclic group is an aromatic heterocyclic polycyclic group, in particular acridinyl, benzimidazolyl, 1,2- or 1,4-benzisothiazinyl, 1,2- or 1,4-benzisoxazinyl, benzisoxazole, benzothiazolyl, benzofuranyl, isobenzofuranyl, 2,3-benzopyronyl, 1,2,3,4-benzotetrazinyl, 1,3,4,6-benzotetrazolyl, benzothiazolyl, 1,2,3- or 1,2,4-benzotriazinyl, 1,2,3- or 2,1,3-benzotriazolyl, benzoxadiazolyl, benzoxazolyl, carbazolyl, cinnolinyl, coumarinyl, indazolyl, indolyl, isoindolyl, indoliziny, purinyl, phenazinyl, phenothiazinyl, phenanthridinyl, phthalazinyl, pteridinyl, quinolinyl, quinoxalinyl, isoquinolinyl, quinazolinyl, quinoliziny, or xanthrenyl.

In a sixth preferred embodiment, the chemical compound of the invention is represented by any of formulas I-V, wherein the mono-heterocyclic group is a saturated or partially saturated heterocyclic polycyclic group, in particular 1,3-benzisodiazolyl, benzomorpholinyl, 1,2- or 1,4-benzopyranyl, 1,3,2-, 1,4,2-, 2,3,1- or 3,1,4-benzoxazinyl, chromanyl, 4H-chromenyl, or indanyl.

In a seventh preferred embodiment, the chemical compound of the invention is represented by any of formulas I-V, wherein the heteroalkyl group is furfuryl, or picolyl.

In its most preferred embodiment, the chemical compound of the invention is

Diethyl 2-(4-fluorophenyl)-2-(3-picolyl)malonate;  
Diethyl 2-(4-nitrophenyl)-2-(2-picolyl)malonate;  
Diethyl 2-(4-nitrophenyl)-2-(4-picolyl)malonate;  
Diethyl 2-phenyl-2-(3-picolyl)malonate;

Diethyl 2-(5-chloro-2-nitro-4-(trifluoromethyl)phenyl)-2-(3-picolyl)malonate;  
Diethyl 2-benzyl-2-(3-picolyl)malonate;  
Diethyl 2-(4-nitrophenyl)-2-[(benzotriazol-1-yl)methyl]malonate;  
Diethyl 2-(2-thienyl)-2-(2-picolyl)malonate;  
5 Diethyl 2-(4-(acetylamino)phenyl)-2-(2-picolyl)malonate;  
Diethyl 2-(4-(benzoylamino)phenyl)-2-(2-picolyl)malonate; or  
2-(4-nitrophenyl)-2-(2-picolyl)malononitril.

### Definition of Substituents

10 In the context of this invention halogen represents a fluorine, a chlorine, a bromine or a iodine atom.

In the context of this invention an alkyl group designates a univalent saturated, straight or branched hydrocarbon chain. The hydrocarbon chain preferably contain of from one to eighteen carbon atoms (C<sub>1-18</sub>-alkyl), more preferred of from  
15 one to six carbon atoms (C<sub>1-6</sub>-alkyl; lower alkyl), including pentyl, isopentyl, neopentyl, tertiary pentyl, hexyl and isohexyl. In a preferred embodiment alkyl represents a C<sub>1-4</sub>-alkyl group, including butyl, isobutyl, secondary butyl, and tertiary butyl. In a preferred embodiment of this invention alkyl represents a C<sub>1-3</sub>-alkyl group, which may in particular be methyl, ethyl, propyl or isopropyl.

20 In the context of this invention a cycloalkyl group designates a cyclic alkyl group, preferably containing of from three to seven carbon atoms (C<sub>3-7</sub>-cycloalkyl), including cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.

In the context of this invention an alkenyl group designates a carbon chain containing one or more double bonds, including di-enes, tri-enes and poly-enes. In a  
25 preferred embodiment the alkenyl group of the invention comprises of from two to six carbon atoms (C<sub>2-6</sub>-alkenyl), including at least one double bond. In a most preferred embodiment the alkenyl group of the invention is ethenyl; 1,2- or 2,3-propenyl; or 1,2-, 2,3-, or 3,4-butenyl.

In the context of this invention an alkynyl group designates a carbon chain  
30 containing one or more triple bonds, including di-yne, tri-yne and poly-yne. In a preferred embodiment the alkynyl group of the invention comprises of from two to six carbon atoms (C<sub>2-6</sub>-alkynyl), including at least one triple bond. In its most preferred

embodiment the alkynyl group of the invention is ethynyl, 1,2- or 2,3-propynyl, 1,2-, 2,3- or 3,4-butynyl.

In the context of this invention an alkoxy group designates an "alkyl-O-" group, wherein alkyl is as defined above.

5 In the context of this invention an acyl group designates a carboxy group (-COOH) or an alkylcarbonyl group (alkyl-CO-), wherein alkyl is as defined above. Examples of preferred acyl groups of the invention include carboxy, acetyl, and propionyl.

In the context of this invention an amido group designates a substituent of  
10 the formula R'-CO-NH- or R'-CO-N(alkyl)-, wherein R' represents hydrogen or an alkyl group as defined above. Examples of preferred amido groups include formamido, acetamido, and propionamido.

In the context of this invention an amino group may be a primary (-NH<sub>2</sub>), secondary (-NH-alkyl), or tertiary (-N(alkyl)<sub>2</sub>) amino group, i.e. it may be substituted  
15 once or twice with an alkyl group as defined above.

In the context of this invention a mono- or polycyclic aryl group designates a monocyclic or polycyclic aromatic hydrocarbon group. Examples of preferred aryl groups of the invention include phenyl, naphthyl and anthracenyl.

In the context of this invention an aralkyl group designates an aryl group  
20 as defined above, which aryl group is attached to an alkyl group as also defined above. Examples of preferred aralkyl groups of the invention include benzyl.

In the context of this invention a mono- or poly-heterocyclic group is a mono- or polycyclic compound, which holds one or more heteroatoms in its ring structure. Preferred heteroatoms include nitrogen (N), oxygen (O), and sulphur (S).  
25 One or more of the ring structures may in particular be aromatic (i.e. a heteroaryl), saturated or partially saturated. Preferred heterocyclic monocyclic groups of the invention include 5- and 6-membered heterocyclic monocyclic groups.

Examples of preferred aromatic heterocyclic monocyclic groups of the invention include 1,3,2,4- or 1,3,4,5-dioxadiazolyl, dioxatriazinyl, dioxazinyl, 1,2,3-,  
30 1,2,4-, 1,3,2- or 1,3,4-dioxazolyl, 1,3,2,4- or 1,3,4,5-dithiadiazolyl, dithiatriazinyl, dithiazinyl, 1,2,3-dithiazolyl, furanyl, furazanyl, imidazolyl, isoimidazolyl, 2-isoimidazolyl, isoindazolyl, isothiazolyl, isoxazolyl, 1,2,3-, 1,2,4-, 1,2,5- or 1,3,4-oxadiazolyl, oxatetrazinyl, oxatriazinyl, 1,2,3,4- or 1,2,3,5-oxatriazolyl, oxazolyl,

pyrazinyl, pyrazolyl, pyridazinyl, pyridinyl, pyrimidinyl, pyrrolyl (azolyl), 1,2,3,4- or 2,1,3,4-tetrazolyl, thiadiazolyl, thiazolyl, thienyl, 1,2,3-, 1,2,4- or 1,3,5-triazinyl, and 1,2,3-, 1,2,4-, 2,1,3- or 4,1,2-triazolyl. Most preferred heterocyclic monocyclic groups of the invention include furan-2-yl, furan-3-yl, 2-, 4- or 5-imidazolyl, 3-, 4- or 5-  
5 isoxazolyl, 1-, 2- or 3-pyridinyl, and 1- or 2-thienyl.

Examples of preferred saturated or partially saturated heterocyclic monocyclic groups of the invention include 1,3,5,6,2-dioxadiazinyl, 1,2,3,4,5-, 1,2,3,5,4-dioxadiazolyl, dioxanyl, 1,3-dioxolyl, 1,3,5,6,2-dithiadiazinyl, 1,2,3,4,5- or 1,2,3,5,4-dithiadiazolyl, 2-isoimidazolyl, isopyrrolyl, isotetrazolyl, 1,2,3- or 1,2,4-  
10 isotriazolyl, morpholinyl, oxadiazinyl, 1,2,4-, 1,2,6-, 1,3,2-, 1,3,6- or 1,4,2-oxazinyl, piperazinyl, piperidinyl, 1,2-, 1,3- or 1,4-pyranyl, and pyrrolidinyl.

Examples of preferred aromatic heterocyclic polycyclic groups of the invention include acridinyl, benzimidazolyl, 1,2- or 1,4-benzisothiazinyl, 1,2- or 1,4-benzisoxazinyl, benzisoxazole, benzothiazolyl, benzofuranyl, isobenzofuranyl, 2,3-  
15 benzopyronyl, 1,2,3,4-benzotetrazinyl, 1,3,4,6-benzotetrazolyl, benzothiazolyl, 1,2,3- or 1,2,4-benzotriazinyl, 1,2,3- or 2,1,3-benzotriazolyl, benzoxadiazolyl, benzoxazolyl, carbazolyl, cinnolinyl, coumarinyl, indazolyl, indolyl, isoindolyl, indolizinyl, purinyl, phenazinyl, phenothiazinyl, phenanthridinyl, phthalazinyl, pteridinyl, quinolinyl, quinoxalinyl, isoquinolinyl, quinazoliny, quinolizinyl, and xanthrenyl.

20 Examples of preferred saturated or partially saturated heterocyclic polycyclic groups of the invention include 1,3-benzisodiazolyl, benzomorpholinyl, 1,2- or 1,4-benzopyranyl, 1,3,2-, 1,4,2-, 2,3,1- or 3,1,4-benzoxazinyl, chromanyl, 4H-chromenyl, and indanyl.

In the context of this invention a hetero-alkyl group designates a mono- or  
25 poly-heterocyclic group as described above, which heterocyclic group is attached to an alkyl group as also defined above. Examples of preferred hetero-alkyl groups of the invention include furfuryl and picolyl.

#### Pharmaceutically Acceptable Salts

The SK/IK/BK channel modulating agents of the invention may be provided  
30 in any form suitable for the intended administration. Suitable forms include pharmaceutically (i.e. physiologically) acceptable salts, and pre- or prodrug forms of the chemical compound of the invention.

Examples of pharmaceutically acceptable addition salts include, without limitation, the non-toxic inorganic and organic acid addition salts such as the acetate derived from acetic acid, the aconate derived from aconitic acid, the ascorbate derived from ascorbic acid, the benzenesulfonate derived from benzenesulfonic acid, the benzoate derived from benzoic acid, the cinnamate derived from cinnamic acid, the citrate derived from citric acid, the embonate derived from embonic acid, the enantate derived from enanthic acid, the formate derived from formic acid, the fumarate derived from fumaric acid, the glutamate derived from glutamic acid, the glycolate derived from glycolic acid, the hydrochloride derived from hydrochloric acid, the hydrobromide derived from hydrobromic acid, the lactate derived from lactic acid, the maleate derived from maleic acid, the malonate derived from malonic acid, the mandelate derived from mandelic acid, the methanesulfonate derived from methane sulphonic acid, the naphthalene-2-sulphonate derived from naphthalene-2-sulphonic acid, the nitrate derived from nitric acid, the perchlorate derived from perchloric acid, the phosphate derived from phosphoric acid, the phthalate derived from phthalic acid, the salicylate derived from salicylic acid, the sorbate derived from sorbic acid, the stearate derived from stearic acid, the succinate derived from succinic acid, the sulphate derived from sulphuric acid, the tartrate derived from tartaric acid, the toluene-p-sulphonate derived from p-toluene sulfonic acid, and the like. Such salts may be formed by procedures well known and described in the art.

Other acids such as oxalic acid, which may not be considered pharmaceutically acceptable, may be useful in the preparation of salts useful as intermediates in obtaining a chemical compound of the invention and its pharmaceutically acceptable acid addition salt.

Metal salts of a chemical compound of the invention includes alkali metal salts, such as the sodium salt of a chemical compound of the invention containing a carboxy group.

The chemical compound of the invention may be provided in unsolved or solvated forms together with a pharmaceutically acceptable solvents such as water, ethanol, and the like. Solvated forms may also include hydrated forms such as the monohydrate, the dihydrate, the hemihydrate, the trihydrate, the tetrahydrate, and the like. In general, solvated forms are considered equivalent to unsolved forms for the purposes of this invention.

### Steric Isomers

The SK/IK/BK channel modulating agents of the present invention may exist in (+) and (-) forms as well as in racemic forms. The racemates of these isomers and the individual isomers themselves are within the scope of the present invention.

5           Racemic forms can be resolved into the optical antipodes by known methods and techniques. One way of separating the diastereomeric salts is by use of an optically active acid, and liberating the optically active amine compound by treatment with a base. Another method for resolving racemates into the optical antipodes is based upon chromatography on an optical active matrix. Racemic  
10 compounds of the present invention can thus be resolved into their optical antipodes, e.g., by fractional crystallisation of d- or l- (tartrates, mandelates, or camphorsulphonate) salts for example.

The chemical compounds of the present invention may also be resolved by the formation of diastereomeric amides by reaction of the chemical compounds of the  
15 present invention with an optically active activated carboxylic acid such as that derived from (+) or (-) phenylalanine, (+) or (-) phenylglycine, (+) or (-) camphanic acid or by the formation of diastereomeric carbamates by reaction of the chemical compound of the present invention with an optically active chloroformate or the like.

Additional methods for the resolving the optical isomers are known in the  
20 art. Such methods include those described by *Jaques J, Collet A, & Wilen S* in "Enantiomers, Racemates, and Resolutions", John Wiley and Sons, New York (1981).

### **Biological Activity**

According to the present invention it has now been found that the isatin derivatives of the invention possess valuable activity as modulators of SK<sub>Ca</sub>, IK<sub>Ca</sub> and/or BK<sub>Ca</sub> channels.

25           The SK/IK/BK channel modulating activity may be monitored using conventional electrophysiological methods such as patch-clamp techniques, or conventional spectroscopic methods such as FLIPR assay (Fluorescence Image Plate Reader; available from Molecular Devices). These methods generally comprises subjecting an SK<sub>Ca</sub>, IK<sub>Ca</sub> or BK<sub>Ca</sub> containing cell to the action of the chemical  
30 compound of the invention, followed by monitoring the membrane potential of the

SK<sub>Ca</sub>, IK<sub>Ca</sub> or BK<sub>Ca</sub> containing cell in order to identify changes in the membrane potential caused by the action of the compound of the invention.

In Example 5 the biological activity of the compounds of the invention is demonstrated using electrophysiologic patch-clamp techniques.

5           Based on their biological activity the compounds of the invention are considered useful for the treatment or alleviation of diseases or conditions responsive to modulation of SK<sub>Ca</sub>, IK<sub>Ca</sub> and/or BK channels, including diseases or conditions like asthma, convulsions, vascular spasms, coronary artery spasms, bladder spasms, urinary incontinence, bladder outflow obstruction, irritable bowel syndrome,  
10   gastrointestinal dysfunction, ischemia, cerebral ischemia, ischaemic hearth disease, angina pectoris, coronary hearth disease, traumatic brain injury, psychosis, anxiety, depression, dementia, memory and attention deficits, Alzheimer's disease, dysmenorrhea, narcolepsy, Reynaud's disease, intermittent claudication, Sjorgren's syndrome, migraine, arrhythmia, hypertension, absence seizures, myotonic muscle  
15   dystrophia, cystic fibrosis, xerostomi, diabetes type II, hyperinsulinemia, premature labour, baldness, cancer, and immune suppression.

### **Pharmaceutical Compositions**

In another aspect the invention provides novel pharmaceutical compositions  
20   comprising a therapeutically effective amount of a chemical compound having SK<sub>Ca</sub>, IK<sub>Ca</sub> or BK<sub>Ca</sub> modulating activity.

While a chemical compound of the invention for use in therapy may be administered in the form of the raw chemical compound, it is preferred to introduce the active ingredient, optionally in the form of a physiologically acceptable salt, in a  
25   pharmaceutical composition together with one or more adjuvants, excipients, carriers, buffers, diluents, and/or other customary pharmaceutical auxiliaries.

In a preferred embodiment, the invention provides pharmaceutical compositions comprising the SK/IK/BK channel modulating agents of the invention, or a pharmaceutically acceptable salt or derivative thereof, together with one or more  
30   pharmaceutically acceptable carriers therefor, and, optionally, other therapeutic and/or prophylactic ingredients, known and used in the art. The carrier(s) must be "acceptable" in the sense of being compatible with the other ingredients of the formulation and not harmful to the recipient thereof.



The pharmaceutical composition of the invention may be administered by any convenient route which suite the desired therapy. Preferred routes of administration include oral administration, in particular in tablet, in capsule, in dragé, in powder, or in liquid form, and parenteral administration, in particular cutaneous, 5 subcutaneous, intramuscular, or intravenous injection. The pharmaceutical composition may be prepared by the skilled person using standard and conventional techniques appropriate to the desired formulation.

The actual dosage depend on the nature and severity of the disease being treated, and is within the discretion of the physician, and may be varied by titration of 10 the dosage to the particular circumstances of this invention to produce the desired therapeutic effect. However, it is presently contemplated that pharmaceutical compositions containing of from about 0.1 to about 500 mg of active ingredient per individual dose, preferably of from about 1 to about 100 mg, most preferred of from about 1 to about 10 mg, are suitable for therapeutic treatments.


15 A satisfactory result can, in certain instances, be obtained at a dosage as low as 0.1  $\mu\text{g/kg}$  i.v. and 1  $\mu\text{g/kg}$  p.o. The upper limit of the dosage range is presently considered to be about 10 mg/kg i.v. and 100 mg/kg p.o. Preferred ranges are from about 0.1  $\mu\text{g/kg}$  to about 10 mg/kg i.v., and from about 1  $\mu\text{g/kg}$  to about 100 mg/kg p.o.











20

## EXAMPLES

The invention is further illustrated with reference to the following examples which are not intended to be in any way limiting to the scope of the invention as claimed.

**Table 1**  
**Substituted malonic acid esters**




entry	A	B	R <sub>1</sub>	R <sub>2</sub>	Mp.	Examples
<b>1a</b>	-	CH <sub>2</sub>			159-61.5*	1, 2
<b>1b</b>	-	CH <sub>2</sub>			161-3*	1, 2
<b>1c</b>	-	CH <sub>2</sub>			174-6*	1, 2
<b>1d</b>	-	CH <sub>2</sub>	Ph		oil	1, 2
<b>1e</b>	-	CH <sub>2</sub>			167-8*	1, 2
<b>1f</b>	CH <sub>2</sub>	CH <sub>2</sub>	Ph		oil	1, 2
<b>1g</b>	-	CH <sub>2</sub>	Ph	OH	oil	3
<b>1h</b>	-	CH <sub>2</sub>	Ph	Oac	oil	4

5

\*as the hydrochloride.

**Example 1**



10

**Diethyl 2-(4-fluorophenyl)-2-(3-picolyl)malonate (1a).** To a solution of diethyl 2-(4-fluorophenyl)malonate (1 g; 3.6 mmol) in anhydrous DMF (10 ml) was added sodium hydride (4.3 mmol, 0.17 g, 60% dispersion in mineral oil). When the evolution of hydrogen had ceased a solution of 3-picolylchloride\* (3.6 mmol) in anhydrous DMF (3 ml) was added and the mixture was heated to 80°C overnight. After cooling four

15

volumes of water was added and the mixture was extracted with ethyl acetate. The organic phase was washed with brine, dried over sodium sulphate and concentrated under reduced pressure. The concentrate was subjected to chromatography on silica gel using a mixture of ethyl acetate and ligroin (1:1) as the eluent. The product  
5 precipitated from the eluate as the hydrochloride upon addition of ethereal hydrogen chloride. Yield: 0.32 g (22%). Mp. 159-161.5°C.

\*3-Picolylchloride was prepared immediately prior to use by liberation from the hydrochloride: 3-picolylchloride, hydrochloride (0.58 g; 3.6 mmol) was dissolved in  
10 water (5 ml). Ethyl acetate and saturated aqueous sodium carbonate was added and the phases were separated. The aqueous phase was extracted twice with ethyl acetate and the combined organic phases were dried over sodium sulphate and evaporated to dryness. This residue was dissolved in DMF and used as described above.

15

The following compounds were prepared analogously:


*Diethyl 2-(4-nitrophenyl)-2-(2-picolyl)malonate (1b)* from diethyl 2-(4-nitrophenyl)malonate and 2-picolylchloride. Yield: 34%. Mp. 161-163°C.

*Diethyl 2-(4-nitrophenyl)-2-(4-picolyl)malonate (1c)* from diethyl 2-(4-nitrophenyl)malonate and 4-picolylchloride. Yield: 23%. Mp. 174-176°C.  
20

*Diethyl 2-phenyl-2-(3-picolyl)malonate (1d)* from diethyl 2-phenylmalonate and 3-picolylchloride. Yield: 58%. M/z: 327 (100%), 281 (43%), 254 (42%), 253 (42%), 235 (51%), 161 (73%).

*Diethyl 2-(5-chloro-2-nitro-4-(trifluoromethyl)phenyl)-2-(3-picolyl)malonate (1e)* from  
25 diethyl 2-(5-chloro-2-nitro-4-(trifluoromethyl)phenyl)malonate and 3-picolylchloride. Yield: 11%. Mp. 167-168°C.


*Diethyl 2-benzyl-2-(3-picolyl)malonate (1f)* from diethyl 2-benzylmalonate and 3-picolyl. Yield: 55% (isolated as the free base). Mp. oil.

**Example 2**

*Diethyl 2-(4-nitrophenyl)malonate.* To a solution of diethyl malonate (6.1 ml; 40 mmol) in anhydrous THF (60 ml) was added sodium hydride (40 mmol, 1.6 g, 60% dispersion in mineral oil). When the evolution of hydrogen had ceased 1-fluoro-4-nitrobenzene (3.9 ml; 36.3 mmol) was added and the mixture was heated to reflux overnight. The solvent was removed under reduced pressure and the residue was suspended in ethyl acetate. Hydrochloric acid (1 M) was added. The phases were separated and the organic phase was dried over sodium sulphate and evaporated to dryness. The residue was triturated with petroleum ether to afford the product as yellow crystals. Yield: 2.44 g (22%).

The following compound was prepared analogously:


*Diethyl 2-(5-chloro-2-nitro-4-trifluoromethylphenyl)malonate* from 2,4-dichloro-5-nitrobenzotrifluoride diethyl malonate. Yield: 54%.

**Example 3**

*Diethyl 2-phenyl-2-(hydroxymethyl)malonate (1g).* To a solution of diethyl 2-phenylmalonate (20 g; 84.6 mmol) and 37% formaline (200 ml) was added diethylamine (8.12 ml; 116 mmol) dropwise at 0°C. The solution was then allowed to stir at ambient temperature for 3 days. The obtained solution was extracted with diethyl ether. The combined organic phases were washed with water, saturated aqueous NaCl-solution, dried over MgSO<sub>4</sub>, filtered and evaporated. After column chromatography on silica gel eluting first with benzine (80-100°C) ethyl acetate 6:1, then 3:1, the product was obtained as a slightly yellowish oil (20.1 g, 89%).

$^{13}\text{C}$  nmr ( $\text{CDCl}_3$ , 125.8 MHz): 170.91, 135.77, 129.66, 128.85, 128.54, 128.29, 127.92, 67.50, 65.63, 62.63, 14.33.

#### Example 4



5

*Diethyl 2-phenyl-2-(acetoxymethyl)malonate (1h).* Diethyl 2-phenyl-2-hydroxymethyl malonate (612 mg; 2.3 mmol) in dry THF (3 ml) was treated with triethylamine (353  $\mu\text{l}$ ; 2.53 mmol), acetic anhydride (240  $\mu\text{l}$ , 2.53 mmol) and a few crystals of 4-dimethylaminopyridine. The obtained solution was stirred for 17 h and then poured into ice-water followed by extraction with diethyl ether. The combined organic fractions were washed with saturated aqueous NaCl-solution and dried over  $\text{MgSO}_4$ , filtered and evaporated. After column chromatography on silica gel eluting with benzine (80-100°C) ethyl acetate 3:1 the product was obtained as a yellow oil (340 mg, 47.9%).

$^{13}\text{C}$  nmr ( $\text{CDCl}_3$ , 25.8 MHz): 170.62, 168.89, 135.19, 128.72, 128.48, 128.30, 66.28, 62.90, 62.43, 21.14, 14.34.

15

#### Example 5

##### Electrophysiological Experiments

In this example, the biological activity of the compounds of the invention is demonstrated using electrophysiologic patch-clamp techniques.

Intermediate-conductance  $\text{Ca}^{2+}$ -activated  $\text{K}^+$  channels (IK channels) have been cloned from human placenta and stably expressed in HEK293 cells. The ionic current through the channels is recorded in the whole-cell mode of the patch-clamp technique.

25

##### Stable Expression of IK in HEK293 Cells

Human IK (hIK) was excised from pT3T7 (GenBank Acc. No. N56819) using EcoR I and Not I, and subcloned into the mammalian expression vector pNS1Z (NeuroSearch), a custom designed derivative of pcDNA3Zeo (Invitrogen), to give the plasmid construct pNS1Z\_hIK.

30

HEK293 tissue culture cells were grown in DMEM (Dulbecco's Modified Eagle Medium) supplemented with 10% FCS (foetal calf serum) at 37°C in 5% CO<sub>2</sub>. One day prior to transfection, 10<sup>6</sup> cells were plated in a cell culture T25 flask. The following day, cells were transfected using lipofection (20 µL Lipofectamin™, Life Technologies, with 2.5 µg of the plasmid pNS1Z\_hIK in a total volume of 540 µL).

The lipofection mixture was overlaid on the cells and incubated at 37°C for 5 hours. The cells were then rinsed with regular media and grown for 72 hours in DMEM, 10% FCS at 37°C in 5% CO<sub>2</sub>.

72 hours post transfection, cells transfected with pNS1Z\_hIK were selected in media supplemented with 0.25mg/ml Zeocin. Single clones were picked and propagated in selection media until sufficient cells for freezing were available. Hereafter the cells were cultured in regular medium without selection agent.

Expression of functional hIK channels was verified by patch-clamp measurements.

#### Whole Cell Recordings

Experiments are carried out on one of several patch-clamp set-ups. Cells plated on coverslips are placed in a 15 µl perfusion chamber (flowrate ~1 ml/min) mounted on a IMT-2 microscope equipped with Nomarski or Hoffmann optics. The microscopes are placed on vibration-free tables in grounded Faraday cages. All experiments are performed at room temperature (20 - 22°C). EPC-9 patch-clamp amplifiers (HEKA-electronics, Lambrect, Germany) are connected to Macintosh computers via ITC16 interfaces. Data are stored directly on the harddisk and analysed by the IGOR software (WaveMetrics, Lake Oswega, USA).

The whole-cell configuration of the patch clamp technique is applied. The tip of a borosilicate pipette (resistance 2-4 MΩ) is gently (remote control system) placed on the cell membrane. Light suction results in a giga seal (pipette resistance increases to more than 1 GΩ) and the cell membrane is then ruptured by more powerful suction. Cell capacitance is electronically compensated and the resistance between the pipette and the cell interior (the series resistance, R<sub>s</sub>) is measured and compensated for. Usually the cell capacitance ranges from 5 to 20 pF (depending on cell size) and the series resistance is in the range 3 to 6 MΩ. R<sub>s</sub> as well as

capacitance compensation are updated during the experiments (before each stimulus).

All experiments with drifting  $R_s$ -values are discharged. Leak-subtractions are not performed.

5

### Solutions

All compounds of Table 1 were subjected to this experiment.

The extracellular (bath) solution contains: 144 mM KCl, 2 mM  $\text{CaCl}_2$ , 1 mM  $\text{MgCl}_2$ , 10 mM HEPES (pH = 7.4). Test compounds are dissolved in DMSO from stock  
10 solution and then diluted to a final concentration of about 10  $\mu\text{M}$  in the extracellular solution. The concentration of  $\text{CaCl}_2$  is 7.6 mM and that of  $\text{MgCl}_2$  is 1.2 mM to give calculated free concentrations of 300 nM and 1 mM, respectively.

### Quantification


15 After establishment of the whole-cell configuration, voltage-ramps (usually -100 to +100 mV) are applied to the cell every 5 sec. A stable baseline current is obtained within a period of 100-300 seconds, and the compounds are then added by changing to an extracellular solution containing the compound to be tested. Very little endogenous current (<200 pA at 100 mV, compared to 2-20 nA IK current) are activated  
20 under these circumstances in native HEK293 cells.

### Results

All compounds tested in this experiment showed activity at a final concentration of about 10  $\mu\text{M}$ , and these compounds therefore are SK/IK/BK channel  
25 modulating agents.

## CLAIMS

1. A chemical compound represented by the general formula



5 wherein


A and B, independently of each another represents a group of the formula -  
(CH<sub>2</sub>)<sub>n</sub>-, of the formula -(CH<sub>2</sub>)<sub>n</sub>-Y- (in either direction), or of the formula -(CH<sub>2</sub>)<sub>n</sub>-Y-  
(CH<sub>2</sub>)<sub>m</sub>-, in which formulas n and m independently of each another represents 0,  
1, 2 or 3, and Y represents O, S, or NR', wherein R' represents hydrogen or alkyl;

10 R<sup>1</sup> and R<sup>2</sup> independently of each another represents an alkyl group; a  
mono- or polycyclic aryl group, which aryl group may optionally be substituted  
one or more times with a substituent selected from the group consisting of  
halogen, CF<sub>3</sub>, CN, amino, nitro, alkoxy, alkyl, alkenyl, alkynyl, phenyl or amido;  
an aralkyl group; a mono- or poly-heterocyclic group, which heterocyclic group  
15 may optionally be substituted one or more times with a substituent selected from  
the group consisting of halogen, CF<sub>3</sub>, CN, amino, nitro, alkoxy, alkyl, alkenyl,  
alkynyl, phenyl or amido; or a hetero-alkyl group, which hetero-alkyl group may  
optionally be substituted one or more times with a substituent selected from the  
group consisting of halogen, CF<sub>3</sub>, CN, amino, nitro, alkoxy, alkyl, alkenyl, alkynyl,  
20 phenyl or amido;

R<sup>3</sup> and R<sup>4</sup> independently of each another represents cyano (CN), an acyl  
group of the formula COOR', an oxo group of the formula COR', or an ether  
group of the formula CH<sub>2</sub>OR', in which groups R' represents hydrogen, alkyl,  
cycloalkyl, or NR''R''', wherein R'' and R''' independently of each another  
25 represents hydrogen or alkyl.

2. The chemical compound according to claim 1, which is a malonic acid ester  
derivative of the general formula






wherein

A, B, R<sup>1</sup> and R<sup>2</sup> are as defined above, and

R<sup>5</sup> and R<sup>6</sup> independently of each another represents hydrogen, alkyl, cycloalkyl, or NR''R''', wherein R'' and R''' independently of each another represents hydrogen or alkyl.

3. The malonic acid ester derivative of claim 2, in which R<sup>5</sup> and R<sup>6</sup> together form a heterocyclic 6-9 membered ring to give a diester derivative of the general formula




wherein

A, B, R<sup>1</sup> and R<sup>2</sup> are as defined above, and

X represents a saturated or unsaturated carbon chain of the formula - (CH<sub>2</sub>)<sub>n</sub>-, wherein n is 1, 2, 3 or 4; of the formula -CH<sub>2</sub>-CH=CH-CH<sub>2</sub>-; of the formula -CH=CH-CH<sub>2</sub>-CH<sub>2</sub>- (in either direction); or of the formula -CH<sub>2</sub>-C≡C-CH<sub>2</sub>-.

4. The chemical compound according to claim 1, which is an oxo derivative of the general formula




wherein

A, B, R<sup>1</sup> and R<sup>2</sup> are as defined above, and

R<sup>5</sup> and R<sup>6</sup> independently of each another represents hydrogen, alkyl, cycloalkyl, or NR''R''', wherein R'' and R''' independently of each another represents hydrogen or alkyl.

5. The chemical compound according to claim 1, which is an ether derivative of the general formula



wherein

- 5           A, B, R<sup>1</sup> and R<sup>2</sup> are as defined above, and

R<sup>5</sup> and R<sup>6</sup> independently of each another represents hydrogen, alkyl, cycloalkyl, or NR''R''', wherein R'' and R''' independently of each another represents hydrogen or alkyl.

- 10 6. The chemical compound according to any of claims 1-5, wherein R<sup>1</sup> and R<sup>2</sup> independently of each another represents an alkyl group; a phenyl or a benzyl group, which phenyl and benzyl groups may optionally be substituted one or more times with substituent selected from the group consisting of halogen, CF<sub>3</sub>, CN, amino or nitro; a mono-heterocyclic group, which heterocyclic group may optionally be substituted one or more times with substituent selected from the group consisting of halogen, CF<sub>3</sub>, CN, amino or nitro; a heteroalkyl group, wherein the heterocyclic group a mono-heterocyclic group, which heterocyclic group may optionally be substituted one or more times with substituent selected from the group consisting of halogen, CF<sub>3</sub>, CN, amino or nitro.

20

7. The chemical compound according to claim 6, wherein R<sup>1</sup> and R<sup>2</sup> independently of each another represents phenyl, 1-, 2 or 3-chlorophenyl, 1-, 2- or 3-chlorobenzyl, 1-, 2- or 3-nitrophenyl, 1-, 2- or 3-nitrobenzyl, 1-, 2 or 3-trifluoromethylphenyl, 1-, 2- or 3-trifluoromethylbenzyl, or 1-nitro-3-trifluoromethyl-5-chlorophenyl, 1-nitro-3-trifluoromethyl-5-chlorobenzyl.

25

8. The chemical compound according to claim 6, wherein the mono-heterocyclic group is an aromatic heterocyclic monocyclic group, in particular 1,3,2,4- or 1,3,4,5-dioxadiazolyl, dioxatriazinyl, dioxazinyl, 1,2,3-, 1,2,4-, 1,3,2- or 1,3,4-dioxazolyl, 1,3,2,4- or 1,3,4,5-dithiadiazolyl, dithiatrizinyl, dithiazinyl, 1,2,3-dithiazolyl, furanyl, furazanyl, imidazolyl, isoimidazolyl, 2-isoimidazolyl,

30

isoindazolyl, isothiazolyl, isoxazolyl, 1,2,3-, 1,2,4-, 1,2,5- or 1,3,4-oxadiazolyl, oxatetrazinyl, oxatriazinyl, 1,2,3,4- or 1,2,3,5-oxatriazolyl, oxazolyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridinyl, pyrimidinyl, pyrrolyl (azolyl), 1,2,3,4- or 2,1,3,4-tetrazolyl, thiadiazolyl, thiazolyl, thienyl, 1,2,3-, 1,2,4- or 1,3,5-triazinyl, or 1,2,3-, 1,2,4-, 2,1,3- or 4,1,2-triazolyl.

9. The chemical compound according to claim 8, wherein the mono-heterocyclic group is 2-furanyl, 3-furanyl, 2-, 4- or 5-imidazolyl, 3-, 4- or 5-isoxazolyl, 1-, 2- or 3-pyridinyl, or 1- or 2-thienyl.

10. The chemical compound according to claim 9, wherein the mono-heterocyclic group is 4-(3,5-dimethyl)-isoxazolyl.

11. The chemical compound according to claim 6, wherein the mono-heterocyclic group is a saturated or partially saturated heterocyclic monocyclic group, in particular 1,3,5,6,2-dioxadiazinyl, 1,2,3,4,5-, 1,2,3,5,4-dioxadiazolyl, dioxanyl, 1,3-dioxolyl, 1,3,5,6,2-dithiadiazinyl, 1,2,3,4,5- or 1,2,3,5,4-dithiadiazolyl, 2-isoimidazolyl, isopyrrolyl, isotetrazolyl, 1,2,3- or 1,2,4-isotriazolyl, morpholinyl, oxadiazinyl, 1,2,4-, 1,2,6-, 1,3,2-, 1,3,6- or 1,4,2-oxazinyl, piperazinyl, piperidinyl, 1,2-, 1,3- or 1,4-pyranyl, or pyrrolidinyl.

12. The chemical compound according to claim 6, wherein the mono-heterocyclic group is an aromatic heterocyclic polycyclic group, in particular acridinyl, benzimidazolyl, 1,2- or 1,4-benzisothiazinyl, 1,2- or 1,4-benzisoxazinyl, benzisoxazole, benzothiazolyl, benzofuranyl, isobenzofuranyl, 2,3-benzopyranyl, 1,2,3,4-benzotetrazinyl, 1,3,4,6-benzotetrazolyl, benzothiazolyl, 1,2,3- or 1,2,4-benzotriazinyl, 1,2,3- or 2,1,3-benzotriazolyl, benzoxadiazolyl, benzoxazolyl, carbazolyl, cinnolinyl, coumarinyl, indazolyl, indolyl, isoindolyl, indolizinyl, purinyl, phenazinyl, phenothiazinyl, phenanthridinyl, phthalazinyl, pteridinyl, quinolinyl, quinoxalinyl, isoquinolinyl, quinazolinyl, quinolizinyl, or xanthrenyl.

13. The chemical compound according to claim 6, wherein the mono-heterocyclic group is a saturated or partially saturated heterocyclic polycyclic group, in

particular 1,3-benzisodiazolyl, benzomorpholinyl, 1,2- or 1,4-benzopyranyl, 1,3,2-, 1,4,2-, 2,3,1- or 3,1,4-benzoxazinyl, chromanyl, 4H-chromenyl, or indanyl.

14. The chemical compound according to claim 6, wherein the heteroalkyl group is  
5       furfuryl, or picolyl.
15. The chemical compound according to claim 1, wherein the chemical compound is  
      Diethyl 2-(4-fluorophenyl)-2-(3-picolyl)malonate;  
      Diethyl 2-(4-nitrophenyl)-2-(2-picolyl)malonate;  
10       Diethyl 2-(4-nitrophenyl)-2-(4-picolyl)malonate;  
      Diethyl 2-phenyl-2-(3-picolyl)malonate;  
      Diethyl               2-(5-chloro-2-nitro-4-(trifluoromethyl)phenyl)-2-(3-  
      picolyl)malonate;  
      Diethyl 2-benzyl-2-(3-picolyl)malonate;  
15       Diethyl 2-(4-nitrophenyl)-2-[(benzotriazol-1-yl)methyl]malonate;  
      Diethyl 2-(2-thienyl)-2-(2-picolyl)malonate;  
      Diethyl 2-(4-(acetylamino)phenyl)-2-(2-picolyl)malonate;  
      Diethyl 2-(4-(benzoylamino)phenyl)-2-(2-picolyl)malonate; or  
      2-(4-nitrophenyl)-2-(2-picolyl)malononitril.  
20
16. A pharmaceutical composition comprising a chemical compound represented by  
the general formula (I) of claims 1-15 for the treatment or alleviation of diseases  
or conditions responsive to modulation of SK<sub>Ca</sub>, IK<sub>Ca</sub> and/or BK<sub>Ca</sub> channels.
- 25 17. The pharmaceutical composition according to claim 16, for the treatment or  
alleviation of asthma, convulsions, vascular spasms, coronary artery spasms,  
bladder spasms, urinary incontinence, bladder outflow obstruction, irritable bowel  
syndrome, gastrointestinal dysfunction, ischemia, cerebral ischemia, ischaemic  
heart disease, angina pectoris, coronary heart disease, traumatic brain injury,  
30       psychosis, anxiety, depression, dementia, memory and attention deficits,  
Alzheimer's disease, dysmenorrhea, narcolepsy, Reynaud's disease, intermittent  
claudication, Sjorgren's syndrome, migraine, arrhythmia, hypertension, absence

seizures, myotonic muscle dystrophia, cystic fibrosis, xerostomi, diabetes type II, hyperinsulinemia, premature labour, baldness, cancer, and immune suppression.

**TITLE: ION CHANNEL MODULATING AGENTS**

5

**ABSTRACT**

The present invention relates to ion channel modulating agents. More particularly, the present invention relates to a particular class of chemical compounds that has proven useful as modulators of SK<sub>Ca</sub>, IK<sub>Ca</sub> and BK<sub>Ca</sub> channels. In further  
10 aspects, the present invention relates to the use of these SK/IK/BK channel modulating agents for the manufacture of medicaments, and pharmaceutical compositions comprising the SK/IK/BK channel modulating agents.

The SK/IK/BK channel modulating agents of the invention are useful for the treatment or alleviation of diseases and conditions associated with the SK/IK/BK  
15 channels.